Physician profile
Remon Obeid
NPI 1215923222
$18,504.70
in general payments reported to CMS, 2019-2025
34 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,684 · 2020: $1,889 · 2021: $2,599 · 2022: $2,613 · 2023: $3,670 · 2024: $3,061 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,470 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,470.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,531.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,032.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,929.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $1,481.30 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Lilly USA, LLC | $1,204.12 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $958.59 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $780.89 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $733.05 | 2021-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $683.53 | 2019-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $650.15 | 2019-2024 | Yupelri, Yupelri |
| Astellas Pharma US INC | $585.96 | 2019-2021 | |
| Dexcom, INC. | $521.22 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $445.11 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $344.53 | 2022-2023 | |
| Abbott Laboratories | $280.10 | 2021-2025 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $238.63 | 2019-2025 | |
| Allergan, INC. | $170.90 | 2019-2020 | |
| Amarin Pharma, INC. | $166.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $146.51 | 2021 | |
| Viatris Specialty LLC | $97.44 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.56 | 2021 | |
| Biogen, INC. | $82.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.13 | 2021-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $48.04 | 2024 | Voquezna |
| Seqirus USA INC | $46.39 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $44.67 | 2024-2025 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $35.20 | 2022-2023 | Rexulti |
| Zealand Pharma US, INC. | $22.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.38 | 2020 | |
| Lundbeck LLC | $17.53 | 2024 | Rexulti |
| Alkermes, INC. | $17.45 | 2023 | Vivitrol |
| Insulet Corporation | $16.99 | 2025 | Omnipod |
| Exact Sciences Corporation | $13.74 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remon Obeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.